ClinicalTrials.gg
RecruitingNCT05809180Updated Apr 20, 2023

Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients

An interventional study of Rituximab and Orelabrutinib in Diffuse Large B Cell Lymphoma, sponsored by The First Affiliated Hospital of Soochow University. Recruiting at 1 site in China. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2023-04-20.

Sponsored by The First Affiliated Hospital of Soochow University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse — 9 open to participants now, 9 under way, 2 of them phase 3. orelabrutinib · Lymphoma, Large B-Cell, Diffuse.

Planned enrollment
7th of 11
35 · median 39
Started
2023
with 1 other
No phase
Only one
of the 11
Registered
5th of 11
by date
Lead sponsor
3 of 11
The First Affiliated Hospital of Soochow University

Among the 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 7th largest by planned enrollment, is one of 2 that started in 2023, is the only one with no phase, and was the 5th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

9 of the 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About orelabrutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

The proposed study is a prospective, single-center and open-ended study in patients over the age of 70 with treatment-naive diffuse large B-cell lymphoma (DLBCL). This study intends to explore a new treatment pattern using Pro-miniCHOP-like regimen and simultaneously evaluate its safety and efficacy for future clinical practice.

Read the detailed description

The study will start with an initial 21-days of induction therapy with combination of orelabrutinib, pomalidomide and rituximab(Pro regimen) in eligible patients, following contrast computed temography(CT) to guide the next treatment. Patients whose lesions have 25% or more reduction will next receive Pro-miniCHOP-like regimen for 6 cycles. Patients with reduction less than 25% will receive R-miniCHOP-like regimen also for 6 cycles. After that, maintenance therapy with pomalidomide for two years will be given to patients undergoing Pro-miniCHOP-like regimen.

03

Conditions studied

  • Diffuse Large B Cell Lymphoma

Keywords

  • Diffuse Large B-Cell Lymphoma
  • Orelabrutinib
  • pomalidomide
  • Rituximab
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histopathologically or confirmed newly diagnosed untreated DLBCL;
  2. There is at least one radiographically (i.e., ≥ 15mm in diameter);
  3. Age ≥ 70 years;
  4. >3 months;
  5. Patients with proper organic function (, , creatinine \< 3 times the ; cardiac ≥ 50%; SPO2>90% under non-oxygenated conditions).
  6. Written obtained from the subject.

Exclusion criteria

Exclusion Criteria:

  1. Patients with severe liver and kidney dysfunction (, , creatinine > 3 times the );
  2. Patients with organic heart disease with clinical symptoms or cardiac dysfunction ( grade ≥2);
  3. Uncontrolled active infection;
  4. Patients with central nervous system DLBCL;
  5. A history of vascular embolism;
  6. Co-existence of other tumors;
  7. Systemic therapy is needed;
  8. Any other psychological conditions that prevent patients from participating in the study or signing the form.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    rituximab(100mg), orelabrutinib(50mg), pomalidomide(4mg), miniCHOP-like

    1. Phase I(induction therapy): Patients receive Rituximab on day 1, Pomalidomide on days 1-7 and oral administration of Orelabrutinib per day. 2. Phase II(stratified response therapy): Part A: (25% or more reduction): Patients receive Pro-miniCHOP-like regimen every 21 days for 6 cycles.(Rituximab on day 1, Pomalidomide on days 1-7, Orelabrutinib per day till progression or intolerant toxicity, Cyclophosphamide on day 2, Doxorubicin/Doxorubicin Liposome on day 2, Vindesine on day 2 and Dexamethasone on days 2-6). Part B: (reduction less than 25%): Patients receive R-miniCHOP-like regimen every 21 days for 6 cycles.(Rituximab on day 1, Cyclophosphamide on day 2, Doxorubicin/Doxorubicin Liposome on day 2, Vindesine on day 2 and Dexamethasone on days 2-6). 3. Phase III(maintenance and follow-up): Patients take Pomalidomide orally on days 1-7 in a cycle of 21 days for 2 years.

    Drug: Rituximab · Drug: Orelabrutinib · Drug: Pomalidomide · Drug: Pro-miniCHOP-like regimen · Drug: R-miniCHOP-like regimen

Interventions

  • Rituximab 375mg/m2 ivgtt d1;

    Also known as: MabThera

  • Orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity;

    Also known as: Yinuokai

  • Pomalidomide 4mg d1-7 each cycle. After Phase II of treatment, single agent pomalidomide 4 mg d1-d7 in 21-day cycles for 2 years.

    Also known as: Anyve

  • DrugPro-miniCHOP-like regimen

    rituximab 375mg/m2 ivgtt d1; orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity; pomalidomide 4mg d1-7; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.

  • DrugR-miniCHOP-like regimen

    rituximab 375mg/m2 ivgtt d1; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate(ORR) after Pro-miniCHOP-like regimen

    The rate of patients who achieved complete response and partial response after Pro-miniCHOP-like regimen.

    Time frame: At the end of cycle 6 (each cycle is 21 days)

  2. Complete Response Rate(CRR) after Pro-miniCHOP-like regimen

    The rate of patients who achieved complete response after Pro-miniCHOP-like regimen.

    Time frame: At the end of cycle 6 (each cycle is 21 days)

Secondary outcomes

  1. Incidence of treatment-emergent adverse events, treatment-related adverse events and serious adverse events

    The safety and tolerability of the therapeutic regimen measured by the incidence of Treatment-Emergent Adverse Events, Treatment-Related Adverse Events and Serious Adverse Events.

    Time frame: Initiation of study drug until 28 days after last dose

  2. Overall Response Rate(ORR) after Pro induction regimen

    The rate of patients who achieved complete response and partial response after Pro induction regimen.

    Time frame: At the end of a cycle 1 of induction therapy period (each cycle is 21 days)

  3. Complete Response Rate(CRR) after Pro induction regimen

    The rate of patients who achieved complete response after Pro induction regimen.

    Time frame: At the end of a cycle 1 of induction therapy period (each cycle is 21 days)

  4. Overall Survival (OS)

    OS will be assessed from the first drug given to date of death or end of follow-up.

    Time frame: Up to 2 years after the end of last patient's treatment

  5. Progression Free Survival (PFS)

    PFS will be assessed from the first drug given to date of progression, relapse, death or end of follow-up.

    Time frame: Up to 2 years after the end of last patient's treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All the data would be available at the First Affiliated Hospital and other researchers after the end of the study.

Supporting information: Study protocol, Statistical analysis plan

Time frame: After the end of the study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jul 2025, 29 months after the start.

Of 40 non-industry interventional studies with no phase under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 144. This study's planned 29 months is below that.

Counting every sponsor, half of 41 studies reached it within 73 months; a quarter within 42 and three quarters within 137.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2023
First posted
Apr 12, 2023
StartActual
Jan 4, 2023
Primary completionEst.
Jul 3, 2025
CompletionEst.
Jul 3, 2026
Last update
Apr 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05809180
Responsible party
Sponsor
First posted
Apr 12, 2023
Start date
Jan 4, 2023
Primary completion
Jul 3, 2025 (estimated)
Completion
Jul 3, 2026 (estimated)
Last update
Apr 20, 2023

Study contacts

Zhengming Jin
Contact
jinzhengming519519@163.com
67781856
Changju Qu
Contact
qcj310@163.com
67781856

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion